Successful salvage therapy of irinotecan for relapsed Hodgkin's lymphoma.

A 30-year-old man, who had a repeated history of relapsed Hodgkin's lymphoma over 7 years, developed bilateral pleural effusion and chest wall involvement. He was treated with weekly irinotecan hydrochloride (CPT-11; 80 mg/m2/week). Partial response was observed after two cycles of irinotecan. Neutropenia and diarrhea were tolerable. This case demonstrated that irinotecan has a therapeutic effect in patients with relapsed Hodgkin's lymphoma.

[1]  T. Tsuruo,et al.  Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo , 2004, Cancer Chemotherapy and Pharmacology.

[2]  T. Saotome,et al.  Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  T. Nakano,et al.  Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma , 1999, Cancer.

[4]  K. Kubo,et al.  Pharmacokinetic characteristics of the novel anticancer agent CPT-11 and its active metabolite in plasma and lung lymph fluid following intravenous administration to sheep. , 1998, Arzneimittel-Forschung.

[5]  Y. Ohashi,et al.  [Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematological Malignancies]. , 1994, Gan to kagaku ryoho. Cancer & chemotherapy.

[6]  T. Taguchi,et al.  Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Y. Nishiwaki,et al.  A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Ohno,et al.  An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.